title: Latent infection by bovine herpesvirus type-5 in experimentally infected rabbits: virus reactivation, shedding and recrudescence of neurological disease.
abstract: Latent infection with bovine herpesvirus type-5 (BHV-5) was established in rabbits inoculated with two South American isolates (EVI-88 and 613) by intranasal or conjunctival routes. Nine rabbits (613, 8/27; EVI-88, 1/34) developed neurological disease and died during acute infection and other three (613, n=2; EVI-88, n=1) developed a delayed neurological disease, at days 34, 41 and 56 post-inoculation (p.i.). Between days 56 and 62 p.i., the remaining rabbits were submitted to five daily administrations of dexamethasone (Dx) to reactivate the infection. Twenty-five out of 44 rabbits (56.8%) shed virus in nasal or ocular secretions after Dx treatment. Virus shedding was first detected at day two post-Dx and lasted from one to 11 days. The highest frequencies of virus reactivation were observed in rabbits inoculated conjunctivally (10/15 versus 15/29); and among rabbits infected with isolate 613 (12/16 versus 13/28). Virus reactivation upon Dx treatment was accompanied by neurological disease in nine rabbits (20.4%), resulting in six deaths (13.6%). Virus in moderate titers and mild to moderate non-suppurative inflammatory changes in the brain characterized the neurological infection. Three other rabbits showed severe neurological signs followed by death after 31 to 54 days of Dx treatment. Virus, viral nucleic acids and inflammatory changes were detected in their brains. The late-onset neurological disease, after acute infection or Dx treatment, was probably a consequence of spontaneous virus reactivation. These results demonstrate that BHV-5 does establish a latent infection in rabbits and that clinical recrudescence may occur upon reactivation.
authors.affiliation: Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria (UFSM), Santa Maria 97105-900, RS, Brazil.
authors.forename: L
authors.initials: L
authors.lastname: Caron
authors.forename: E F
authors.initials: EF
authors.lastname: Flores
authors.forename: R
authors.initials: R
authors.lastname: Weiblen
authors.forename: C F C
authors.initials: CF
authors.lastname: Scherer
authors.forename: L F
authors.initials: LF
authors.lastname: Irigoyen
authors.forename: P M
authors.initials: PM
authors.lastname: Roehe
authors.forename: A
authors.initials: A
authors.lastname: Odeon
authors.forename: J H
authors.initials: JH
authors.lastname: Sur
mesh_terms: D000208:Acute Disease; D000281:Administration, Intranasal; D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000821:virology; D002460:Cell Line; D002540:Cerebral Cortex / Q000821:virology; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004195:Disease Models, Animal; D018792:Encephalitis, Viral / Q000662:veterinary* / Q000821:virology; D006566:Herpesviridae Infections / Q000662:veterinary* / Q000821:virology; D025881:Herpesvirus 5, Bovine / Q000187:drug effects / Q000472:pathogenicity / Q000502:physiology*; D008590:Meningoencephalitis / Q000662:veterinary* / Q000821:virology; D011817:Rabbits; D014775:Virus Activation / Q000187:drug effects; D017735:Virus Latency; D014779:Virus Replication; D017201:Virus Shedding
chemical_list: D003907:Dexamethasone